Summary by Futu AI
Kingsun Pharmaceutical Co., Ltd.-B (stock code: 2511.HK) announced that the two Phase III clinical registration trials for its self-developed HTD1801 to treat type 2 diabetes have completed patient enrollment. The two trials, SYMPHONY-1 and SYMPHONY-2, respectively evaluate the effect of HTD1801 on glycated hemoglobin and glucose metabolism indicators in patients with type 2 diabetes. HTD1801 is a new type of oral intestinal and hepatic anti-inflammatory and metabolic regulator. China is currently the country with the largest number of type 2 diabetes patients in the world. The development of HTD1801 is of great significance in meeting unmet medical needs. Kingsun Pharmaceutical is a global biopharmaceutical company focused on developing multifunctional and multi-target therapy. HTD1801 has been granted Fast Track and orphan drug designation by the FDA in the United States and has also been included as a Major New Drug Creation Science and Technology Special Project in China. The company reminds shareholders and potential investors that there is still uncertainty in the successful development and launch of HTD1801 and caution should be exercised when investing.